Finally, silibinin modulates the immune microenvironment by reducing NF-κB-regulated cytokines, such as IL-6, IL-8, and CCL2, which limits TAM recruitment and dampens inflammation-driven tumor growth [110,112]. This evidence concerns the gene CCL2 and neoplasm.